Trastuzumab, bevacizumab, and paclitaxel for HER2-positive stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of anti-cancer medicines for HER2-positive advanced stomach cancer that has already been treated once. It may help shrink tumors and slow the disease by targeting HER2 and blocking tumor blood supply.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach cancer that is HER2-positive (based on lab tests like IHC, or a gene test like SISH/FISH).
- Your cancer has gotten worse after one prior stomach cancer treatment given through the bloodstream.
- You are 19 years or older and can sign a written consent form.
- You have at least one measurable or assessable tumor spot on scans.
- Your health status is good enough (ECOG 0–2) and your labs/organ function meet required thresholds.
- Your heart pumping strength is strong enough (echo EF ≥55% or MUGA scan ≥50%).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted drugs, trastuzumab deruxtecan and afatinib, together for advanced stomach or gastroesophageal junction cancer that has low levels of the HER2 protein. The goal is to see if the combination shrinks tumors or slows cancer growth.
This trial tests whether combining different drugs before and after surgery can help people with locally advanced stomach cancer that can't be removed right away. The goal is to see which combination works best to shrink the tumor and improve outcomes.
This trial tests a combination of three drugs after surgery for HER2-positive stomach cancer: an immunotherapy (serplulimab), a targeted therapy (trastuzumab), and chemotherapy (SOX). The goal is to see if this treatment helps prevent the cancer from coming back.
This trial tests adding pembrolizumab to standard trastuzumab and chemotherapy for people with HER2-positive stomach or esophageal cancer that can be fully removed with surgery. The goal is to see if this combination improves outcomes before and after surgery.
This trial tests a combination of three drugs (targeted therapy, immunotherapy, and chemotherapy) before and after surgery for locally advanced HER2-positive stomach cancer. It aims to see if this treatment can improve outcomes for patients whose cancer has not yet spread.
This Phase 2 trial tests adding chemotherapy plus trastuzumab and toripalimab around the time of surgery for HER2-positive, locally advanced stomach or esophagus-stomach junction cancer. It aims to shrink the cancer and reduce the chance it comes back by attacking it through more than one pathway.
Hear when a new HER2-positive Advanced Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.